HC Wainwright Reaffirms “Buy” Rating for ObsEva SA (OBSV)
A number of other brokerages have also issued reports on OBSV. Zacks Investment Research lowered shares of ObsEva SA from a hold rating to a sell rating in a report on Saturday, August 19th. Leerink Swann reissued an outperform rating and issued a $18.00 price target on shares of ObsEva SA in a report on Wednesday, August 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $23.25.
ObsEva SA (NASDAQ:OBSV) opened at 6.93 on Friday. The company has a 50-day moving average of $7.51 and a 200 day moving average of $8.54. ObsEva SA has a 12-month low of $5.00 and a 12-month high of $14.69. The firm’s market cap is $197.48 million.
ObsEva SA (NASDAQ:OBSV) last announced its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.13. During the same period last year, the company earned ($0.30) EPS. Equities analysts expect that ObsEva SA will post ($2.32) EPS for the current fiscal year.
Several large investors have recently bought and sold shares of the company. Baker Avenue Asset Management LP purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $104,000. Paloma Partners Management Co purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $131,000. Sphera Funds Management LTD. lifted its position in shares of ObsEva SA by 9.7% in the 2nd quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after purchasing an additional 20,411 shares during the period. Iguana Healthcare Management LLC purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $260,000. Finally, Spark Investment Management LLC purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $518,000. 48.46% of the stock is owned by hedge funds and other institutional investors.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Stock Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related stocks with our FREE daily email newsletter.